CCL

Összesen 2 találat.
#/oldal:
Részletezés:
Rendezés:

1.

001-es BibID:BIBFORM016334
Első szerző:Francz Mónika (patológus)
Cím:Comparison of Pathvysion and Poseidon HER2 FISH assays in measuring HER2 amplification in breast cancer : a validation study / Monika Francz, Kristof Egervari, Laszlo Kardos, Judit Toth, Zoltan Nemes, Janos Szanto, Zoltan Szollosi
Dátum:2010
ISSN:0021-9746
Megjegyzések:The current study was done as a validation study prior to setting up a clinical HER2 testing service using the new commercial Poseidon HER2 fluorescence in situ hybridisation (FISH) assay. However, it was felt that the experience of the authors of this study may be of interest to other laboratories when considering setting up a HER2 diagnostic facility. METHODS: 122 patients who had been diagnosed with invasive breast cancer were selected. Immunolabelling with HercepTest, PathVysion and Poseidon FISH assays were carried out using tissue microarray blocks. RESULTS: Concordance correlation coefficients showed near perfect agreement in average HER2 and centromere specific signal counts per cell and in the HER2/CEP17 ratios between the PathVysion and the Poseidon FISH assays. In addition, the kappa measure showed perfect agreement (kappa 0.9441, p<0.0001), and if only 2+ cases were considered there was substantial agreement (kappa 0.7671, p=0.0006), between the two assays. The sensitivity and the specificity of the Poseidon FISH kit were calculated to be 95.2% and 100%, respectively, whereas the positive predictive value (PPV) and negative predictive value (NPV) were 100% and 99%, respectively. With regard to the ability to presume HER2 polysomy, the Poseidon FISH kit had a sensitivity of 93.3% and a specificity of 99.1%, with PPV and NPV of 93.3% and 99.1%, respectively, as assessed with PathVysion classification as the reference. CONCLUSIONS: Statistical analysis confirmed that the two FISH assays are comparable in terms of detection of HER2 gene amplification. Proceeding from these findings, the genetic diagnoses obtained with the Poseidon kit can be considered to be as valuable as the results from the Food and Drug Administration approved PathVysion assay, and its utilisation in routine HER2 diagnostics is proposed.
Tárgyszavak:Orvostudományok Elméleti orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:Journal Of Clinical Pathology. - 63 : 4 (2010), p. 341-346. -
További szerzők:Egervári Kristóf (1983-) (patológus) Kardos László (1970-) (megelőző orvostan és népegészségtan szakorvos) Tóth Judit (1958-) (onkológus szakorvos) Nemes Zoltán (1942-) (patológus) Szántó János (1949-) (onkológus szakorvos) Szöllősi Zoltán
Internet cím:Intézményi repozitóriumban (DEA) tárolt változat
DOI
Szerző által megadott URL
Borító:

2.

001-es BibID:BIBFORM006447
Első szerző:Tóth Judit (onkológus szakorvos)
Cím:Analysis of EGFR gene amplification, protein over-expression and tyrosine kinase domain mutation in recurrent glioblastoma / Judit Toth, Kristof Egervari, Almos Klekner, Laszlo Bognar, Janos Szanto, Zoltan Nemes, Zoltan Szollosi
Dátum:2009
ISSN:1219-4956 (Print)
Megjegyzések:Gefitinib and erlotinib are both selective EGFR tyrosine kinase inhibitors (EGFR-TKIs) that have produced responses in a small subgroup of lung cancer patients. The strongest evidence for a role of EGFR in the biology of glioblastoma stems from clinical trials in which 15?20% of recurrent glioblastoma patients experienced significant tumour regression in response to these small-molecule EGFR kinase inhibitors. We examined the protein-kinase domain of the EGFR gene, EGFR protein expression and EGFR gene amplification in 20 cases of recurrent GBMs. EGFR protein over-expression was found in 65% of cases. EGFR protein over-expression was associated with EGFR gene amplification in 35% of cases, and with high polysomy in 15% of cases. No mutations were found in the TK domain of the EGFR gene. Our results confirm that mutations in the kinase domain are absent in recurrent GBM, and this might be a preponderant factor in the lack of major clinical responses of TKIs in GBM, recent studies have suggested that responsiveness to EGFR kinase inhibitors was strongly associated with coexpression of EGFRvIII and PTEN. Further prospective validation of EGFRvIII and PTEN as predictors of the clinical response to EGFR kinase inhibitors in recurrent GBM is strongly anticipated.
Tárgyszavak:Orvostudományok Elméleti orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Glioblastoma multiforme
EGFR
Kinase inhibitor treatment
Megjelenés:Pathology and Oncology Research. - 15 : 2 (2009), p. 225-229. -
További szerzők:Egervári Kristóf (1983-) (patológus) Klekner Álmos (1970-) (idegsebész) Bognár László (1958-) (idegsebész, gyermekidegsebész) Szántó János (1949-) (onkológus szakorvos) Nemes Zoltán (1942-) (patológus) Szöllősi Zoltán
Internet cím:DOI
elektronikus változat
Borító:
Rekordok letöltése1